恒瑞医药:公司及子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4508片、注射用SHR-A1811、阿得贝利单抗注射液、贝伐珠单抗注射液的《药物临床试验批准通知书》,将于近期开展临床试验。恒瑞医药:近日,公司收到国家药品监督管理局(简称“国家药监局”)下发的《受理通知书》,公司海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理。康缘药业:公司近日...
Source Link恒瑞医药:公司及子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4508片、注射用SHR-A1811、阿得贝利单抗注射液、贝伐珠单抗注射液的《药物临床试验批准通知书》,将于近期开展临床试验。恒瑞医药:近日,公司收到国家药品监督管理局(简称“国家药监局”)下发的《受理通知书》,公司海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理。康缘药业:公司近日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.